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                                      The discovery that persistent infection with oncogenic human pap-
illomavirus (HPV) types, of which 15 have been identified (  1  ), is a 
necessary cause of cervical cancer has driven the development of 
prophylactic vaccines that are based on the capsid proteins L1 and 
L2 (  2  ). Vaccination with L1 virus-like particles (VLPs) (  3    –    5  ) elicits 
high, but type-restricted, titers of neutralizing antibodies, which 
appear to be the main mediators of protection (  3  ,  6    –    9  ). VLP vaccines 
confer a high degree of protection against infection and neoplastic 
disease caused by the papillomavirus types used to derive the vaccine 
(  10    –    12  ). Current formulations of the two licensed L1 VLP vaccines 
(Gardasil, Merck & Co., Inc., and Cervarix, GlaxoSmithKline) con-
tain two oncogenic HPV genotypes, HPV-16 and HPV-18, which 
together account for about 70% of cervical cancers (  11  ,  13  ). Gardasil 
also contains L1 VLP types that are derived from HPV-6 and HPV-
11 and prevents benign genital warts caused by these viruses. 
  If protection induced by L1 VLP vaccines is predominantly HPV 
type speciﬁ  c, it would be necessary to incorporate VLPs from nine 
oncogenic HPV types to prevent greater than 90% of cervical 
cancers (  14  ). Although L1 VLP vaccination may induce partial cross-
protection against very closely related HPV types (  12  ,  15  ), which is 
likely mediated by relatively low levels of cross-type neutralizing 
antibodies (  8  ,  16  ), comprehensive vaccination against all oncogenic 
HPV types is challenging because of the cost and complexity of devel-
oping highly multivalent L1 VLP vaccines (  17  ). The possibility of a 
single protein, inexpensive, pan-oncogenic HPV vaccine is an attrac-
tive alternative to highly multivalent and thus costly L1 VLP  vaccines. 
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     Background     Vaccination with minor capsid protein L2 induces antibodies that cross-neutralize diverse papillomavirus 
types. However, neutralizing antibody titers against the papillomavirus type from which the L2 vaccine 
was derived are generally higher than the titers against heterologous types, which could limit effective-
ness against heterologous types. We hypothesized that vaccination with concatenated multitype L2 fusion 
proteins derived from known cross-protective epitopes of several divergent human papillomavirus (HPV) 
types might enhance immunity across clinically relevant HPV genotypes.   
     Methods     Antibody responses of mice (n    =    120) and rabbits (n    =    23) to vaccination with HPV-16 amino-terminal L2 poly-
peptides or multitype L2 fusion proteins, namely, 11-200 × 3 (HPV types 6, 16, 18), 11-88 × 5 (HPV types 1, 5, 
6, 16, 18), or 17-36 × 22 (five cutaneous, two mucosal low-risk, and 15 oncogenic types), that were formu-
lated alone or in GPI-0100, alum, or 1018 ISS adjuvants were compared with vaccination with L1 virus-like 
particles (VLPs), including Gardasil, a licensed quadrivalent HPV L1 vaccine, and a negative control. Mice 
were challenged with HPV-16 pseudovirions 4 months after vaccination. Statistical tests were two-sided.   
     Results     The HPV-16 L2 polypeptides generated robust HPV-16  –  neutralizing antibody responses, albeit lower than 
those to HPV-16 L1 VLPs, and lower responses against other HPVs. In contrast, the antisera to the multi-
type L2 fusion proteins 11-200 × 3 and 11-88 × 5 induced high neutralizing antibody titers against all het-
erologous HPVs tested. 11-200 × 3 formulated in GPI-0100 adjuvant or alum with 1018 ISS protected mice 
against HPV-16 challenge (reduction in HPV-16 infection vs phosphate-buffered saline control,   P   < .001) 
4 months after vaccination as well as HPV-16 L1 VLPs, but 11-200 × 3 alone or formulated with either alum 
or 1018 ISS was less effective (reduction in HPV-16 infection,   P   < .001).   
     Conclusion     Concatenated multitype L2 proteins in adjuvant have potential as pan-oncogenic HPV vaccines.   
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Preclinical studies have shown that immunization of cows (  18    –    20  ) 
or rabbits (  21    –    24  ) with L2 polypeptides protects against experi-
mental challenge by the homologous animal papillomavirus at 
mucosal sites in the bovine papillomavirus (BPV) type 4/cattle 
model and at cutaneous sites in the cottontail rabbit papillomavirus 
(CRPV)/rabbit model. 
  In addition to papillomavirus type  –  speciﬁ  c protection, vaccina-
tion with amino-terminal L2 polypeptides has also induced a 
remarkable degree of protection against animal challenge with 
heterologous papillomavirus types (  24  ,  25  ). Notably, vaccination 
with HPV-16 L2 11-200 protects against cutaneous and mucosal 
challenge with CRPV and the rabbit oral papillomavirus, respec-
tively, both of which are evolutionarily divergent from HPV-16 
(  24  ). In addition, vaccination with HPV-16 11-200 or BPV-1 1-88 
L2 peptides generated sera with cross-neutralizing antibodies 
against diverse HPV types (  26  ). Protection induced by homolo-
gous and heterologous L2 polypeptides appears to be mediated by 
neutralizing antibodies because the induction of neutralizing anti-
bodies against CRPV L2 was associated with protection against 
challenge with infectious CRPV virions in individual rabbits (  24  ). 
Cell-mediated immunity does not appear to play a role because 
inoculation with CRPV DNA induced similar papilloma burdens 
in naive rabbits and animals that had been completely protected 
from challenge by CRPV virions by vaccination with L2. 
  These observations suggest that an L2-based vaccine might have 
potential as a pan-HPV vaccine, with activity against nongenital papil-
lomaviruses in addition to those that cause cervical and other mucosal 
cancers and those that cause genital warts. However, a disadvantage of 
monovalent L2 immunogens is that the neutralizing titers and protec-
tion induced by them are greater for the homologous-type virus than 
for a heterologous-type papillomavirus, that is, although L2 induces 
antibodies that cross-neutralize diverse papillomavirus types, they 
neutralize the homologous type more effectively (  26  ,  27  ). The lower 
immune response to heterologous HPVs could severely limit the 
practical utility of an L2-based vaccine because its breadth and dura-
tion of protection are likely to depend on the ability to induce robust 
neutralizing activity against heterologous HPV types. To address this 
issue and provide broader immunity, we have here examined concat-
enated multitype L2 fusion proteins for their ability to induce cross-
neutralizing antibodies against several clinically relevant HPV types. 
  Cross-linking of B-cell receptors by arrays of epitopes on VLPs 
(  28  ,  29  ) or polymers (  30  ,  31  ) potentiates B-cell activation. We hypoth-
esized that B-cell receptors recognizing concatenated neutralization 
epitopes of L2 of multiple different HPV genotypes would be pref-
erentially activated as compared with L2 type  –  speciﬁ  c B-cell recep-
tors, and thus, B cells presenting the former would be more readily 
activated and bias the global repertoire of neutralizing antibody 
response to cross-reactive epitopes. We have tested this hypothesis 
by examining whether vaccination with concatenated multitype L2 
fusion proteins enhances the breadth and titer of cross-neutralizing 
antibodies as compared with a monotypic L2 immunogen. 
    Methods 
    Antigen Preparation 
  HPV-16 L2 polypeptide expression constructs encompassing 
residues 1  –  88, 13  –  88, 1  –  107, 13  –  107, 11  –  200, 13  –  200, and 89  –  200 
were generated by polymerase chain reaction as described previ-
ously (  26  ). The multitype L2 constructs were codon optimized 
for   Escherichia coli   expression by lowest free-energy calculation 
and synthesized by Blue Heron Biotechnology, Inc. (Bothell, 
WA), with 5  ′     Bam  HI and 3  ′     Xho  I sites to facilitate cloning. The 
L2 genes were subcloned into the pET28a vector (Novagen, San 
Diego, CA) and the resulting hexahistidine (6His)-tagged recom-
binant polypeptides expressed in   E coli   BL21 (Rosetta cells; 
Novagen) (  26  ). The recombinant L2 polypeptides were affinity 
purified by binding to a nickel  –  nitrilotriacetic acid column 
(Qiagen, Valencia, CA) in 8 M urea (using the QiaExpressionist 
standard purification protocol for denaturing conditions) and 
then dialyzed in cassettes (Pierce, Rockland, NJ) against phos-
phate-buffered saline (PBS, 137 mM NaCl, 12 mM phosphate, 
2.7 mM KCl). Purity was monitored by sodium dodecyl sulfate  –
  polyacrylamide gel electrophoresis and protein concentration 
determined by bicinchoninic acid test (Pierce) using a bovine 
serum albumin (BSA) standard. HPV-16 and HPV-45 L1 VLPs 
were prepared in 293TT cells (  32  ) as for pseudovirions but 
  without L2.   
    Enzyme-Linked Immunosorbent Assays of L2 or HPV-16 
Pseudovirion–Specific Serum Antibody Titers 
  Pseudovirions were prepared as previously described       (  32  ). 
Immobilon plates (Nunc, Rochester, NY) were coated overnight at 
4°C with 100 ng/well of 6His  –  HPV-16 L2 prepared in   E coli   or 
HPV-16 L1/L2 pseudovirions produced in 293TT cells and 
diluted in PBS. Wells were then blocked with 1% BSA  –  PBS for 
1 hour at room temperature and incubated with twofold dilutions 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Current human papillomavirus (HPV) vaccines are based on capsid 
L1 proteins and appear to confer only HPV type  –  specific immunity. 
Although vaccination with minor capsid protein L2 induces anti-
bodies that neutralize many types of papillomaviruses, the 
response to the specific virus type is usually higher than it is to 
other types.   
    Study design 
  Mice were vaccinated with HPV-16 L2 polypeptides, multitype L2 
fusion proteins in different adjuvants, Gardasil, HPV-16 L1 virus-
like particles (VLPs), or a negative control, followed by challenge 
with HPV-16 pseudovirions 4 months later.   
    Contributions 
  Vaccination with the multitype L2 fusion proteins induced antibody 
responses to all HPV types tested and protected mice against 
HPV-16 challenge as well as HPV-16 L1 VLPs.   
    Implications 
  Multitype L2 proteins have potential as pan-oncogenic HPV 
vaccines.   
    Limitations 
  To be effective in humans, the vaccine will need to protect against 
infection for several years; only short times were tested in this study. 
    From the Editors       
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of rabbit or mouse antisera for 1 hour at room temperature. Following 
a wash step with PBS/0.01% (vol/vol) Tween-20, peroxidase-labeled 
goat anti-rabbit IgG (KPL, Inc., Gaithersburg, MD) diluted 1:5000 
in 1% BSA/PBS was added for 1 hour. The plates were then washed 
again and developed with 2,2  ′  -azino-bis(3-ethylbenzthiazoline-6-
sulfonic) acid solution (Roche       Applied Science, Indianapolis, IN) for 
10 minutes (  33  ). The absorbance was measured at 405 nm (  A    405  ) in a 
Benchmark Plus ELISA plate reader (Bio-Rad, Hercules, CA). Single 
assays were performed in parallel using preimmune sera as a negative 
control and mouse monoclonal antibody RG-1 or rabbit antiserum to 
the coating antigen as positive controls.   
    Antibody Neutralization Assays 
  The papillomavirus pseudovirion in vitro neutralization assays were 
performed as described earlier (  32  ), and the secreted alkaline phos-
phatase activity in the cell-free supernatant was determined using 
  p  -nitrophenyl phosphate (Sigma Aldrich, St Louis, MO) dissolved in 
diethanolamine, with absorbance measured at 405 nm. Constructs 
and detailed protocols for the preparation of the pseudovirions can be 
found at   http://home.ccr.cancer.gov/lco/  . Titers were defined as the 
reciprocal of the highest dilution that caused a greater than 50% 
reduction in   A    405  , as described previously (  32  ), and a titer less than 50 
was considered not detected. Single assays were performed in parallel 
using preimmune sera as a negative control and mouse monoclonal 
antibody RG-1 or rabbit antiserum to L1 VLP as positive controls.   
    Vaccine Studies 
  Studies in animals were performed in accordance with institutional 
policies and with the approval of the Johns Hopkins Animal Care 
and Use Committee or the Animal Ethics committee of Shantha 
Biotechnics, Hyderabad, India, using standard protocols. Balb/c 
mice (n    =    120, from NCI, Frederick, MD) were vaccinated in 
groups of five mice three times at 2-week intervals by subcutane-
ous injection with 10   µ  g of HPV-16 or HPV-45 L1 VLP, or the 
adjuvants alum (1.3 mg), or 1018 ISS alone (10   µ  g/mouse), or 
25   µ  g of recombinant L2-based antigens including 11-200 × 1, 
11-200 × 3, 1-88 × 1, 11-88 ×       5, 17-36 × 22, or HPV-16 L2 17-36 
peptide prepared by chemical synthesis (Sigma Aldrich, St Louis, 
MO      ) in the formulations indicated: PBS alone, or alum alone (1.3 
mg), or 1018 ISS alone (10   µ  g/mouse), or 25   µ  g 11-200 × 3 alone, 
or formulated with alum (1.3 mg), or with 1018 ISS (10   µ  g/mouse), 
or with GPI-0100 (at either 50 or 200   µ  g/mouse), or with GPI-
0100 (50   µ  g/mouse) + Tween-40 (1 mg/mouse), or with alum and 
1018 ISS (10   µ  g/mouse). Blood samples were obtained from the 
tail vein 2 weeks after the final immunization. Rabbits (n    =    15) were 
vaccinated on days 1, 28, 42, 60, and 76 with 300   µ  g of HPV-16 
L2 polypeptide or polymeric L2 constructs in complete Freund  ’  s 
adjuvant (CFA) with the initial dose and incomplete Freund’s adju-
vant (IFA) thereafter per standard protocols. Rabbits (n    =    8) were 
vaccinated with 12 or 30   µ  g of Gardasil on days 1, 21, 35, and 56, 
and blood samples were collected 1 week after the final vaccina-
tion. Blood was allowed to congeal overnight, and the serum was 
separated by centrifugation and stored at     20°C until use.   
    Cutaneous HPV-16 Challenge 
  At 4 months after vaccination, the above mice were challenged 
with HPV-16 pseudovirions as described previously (  25  ,  34  ). 
Briefly, all mice were anesthetized, and a patch of skin on their 
ventral torso was shaved with an electric razor while taking care 
not to traumatize the epithelium, before challenge by application 
of approximately 3 × 10  9   HPV-16 pseudovirion particles (100 ng 
protein) that encapsidated pYLUC, a plasmid carrying a luciferase 
gene that would be expressed upon pseudoinfection (  http://
home.ccr.cancer.gov/lco/  ) in 10   µ  L 0.6% carboxymethylcellulose 
(Sigma Aldrich) to the patch of shaved skin on each mouse [all 
parameters were defined previously (  25  ,  34  )]. Three days later, all 
mice were again anesthetized by isoflurane inhalation (  ~  1%), 
injected intraperitoneally with luciferin (100   µ  L at 7 mg/mL), 
and their image was acquired for 10 minutes [timing previously 
optimized (  25  ,  34  )] with an IVIS 200 bioluminescence imaging 
system (Xenogen, Cranbury, NJ) to visualize the expression of 
luciferase by measuring light emission. Equal areas encompassing 
the site of virus inoculation were analyzed using Living Image 
2.20 software (Xenogen). Bioluminescence levels above that of 
mice vaccinated with HPV L1 VLPs before challenge was 
determined.  
    Statistical Analysis 
  Comparison between groups for titers and levels of infection in the 
mouse model was made by multiway analysis of variance with 
Bonferroni adjustment (Statview 5.0; SAS Institute, Inc., Cary, 
NC). All statistical tests were two-sided, and   P   values less than .05 
were considered statistically significant.     
    Results 
  We first sought to determine whether we could identify an opti-
mal monovalent L2 immunogen. The L2 vaccines comprising 
residues 1  –  88 and 11  –  200 used in earlier studies to demonstrate 
induction of cross-neutralizing antibodies and protection against 
heterologous challenge had been selected based on the presence 
of convenient restriction sites in L2 DNA, rather than immuno-
genicity considerations (  35  ,  36  ). Although vaccination with either 
peptide was protective, there was some suggestion that the cross-
neutralization and cross-protection might be more effective with 
the 11  –  200 peptide than with the 1  –  88 peptide (  24  ). Consistent 
with this possibility, vaccination with L2 peptides from 94  –  112 
and 107  –  122 had been found to be protective against homologous 
challenge (  23  ). Therefore, to assess the potential benefit to immu-
nogenicity of including these regions within an L2 vaccine, we 
generated amino-terminal L2 polypeptides that terminated at 
residues 88, 107, and 200 (  Table 1  ). We also tested the influence 
on immunogenicity of starting the L2 polypeptide at various 
amino-terminal amino acid residues. During infection, L2 must 
be cleaved by furin to remove residues 1  –  13 (  37  ), and this cleav-
age renders a conserved neutralization epitope between residues 
17 and 36 (  16  ) more accessible to monoclonal antibody RG-1 
(  38  ). For these vaccine studies, we therefore generated amino-
terminal L2 polypeptides initiating at residues 1 and 11, as bench-
mark sites known from the earlier studies to be immunogenic; 
residue 13, as an immunogen whose amino terminus mimicked 
what would be present after furin cleavage; and residue 89, to 
assess the role of amino acids downstream from residues 1  –  88 
(  Table 1  ).         jnci.oxfordjournals.org    JNCI | Articles 785
    Responses in Rabbits Vaccinated With Monomeric and 
Multimeric L2 Polypeptides 
  To map immunogenicity for homologous and cross-neutralization 
epitopes, seven HPV-16 L2 polypeptides (  Table 1  ) were expressed 
in   E coli   with 6-His tags and affinity purified for vaccination stud-
ies. Although all the polypeptides were readily purified, two, 
HPV-16 L2 13  –  88 and 89  –  200, were unstable during manufactur-
ing. Rabbits were vaccinated five times with 300   µ  g of each poly-
peptide, in CFA for the priming dose and in IFA for the booster 
vaccinations. The success of each vaccination was first verified by 
testing the hyperimmune sera in an enzyme-linked immunosor-
bent assay (ELISA) to detect full-length HPV-16 L2 and an 
ELISA to detect HPV-16 L1/L2 pseudovirions. High titers of 
serum antibodies were raised to each HPV-16 L2 polypeptide, 
although the titers against HPV-16 pseudovirions were lower for 
the antisera raised with the two unstable antigens, L2 13  –  88 and 
89  –  200 (  Table 1  ). HPV-16  –  neutralizing titers and HPV-6, 
HPV-18, HPV-31, HPV-45, and HPV-58 cross-neutralizing 
titers were then determined for each rabbit antiserum induced by 
the L2 polypeptides (  Table 1  ). Consistent with earlier studies (  24  ), 
the HPV-16 L2 1  –  88 and 11  –  200 peptides induced robust titers of 
HPV-16  –  neutralizing antibodies. Similarly, robust HPV-16  –
  neutralizing antibody titers were observed for the antisera to 
HPV-16 L2 1 –  107, 13 –  107, and 13 –  200. Vaccination with HPV-16 
L2 13  –  88 and 89  –  200 proteins that were unstable produced con-
siderably weaker neutralizing responses. 
  The L2-speciﬁ  c antisera induced by the various HPV-16 L2 
peptides neutralized not only HPV-16 but also the diverse range 
of heterologous papillomavirus types, including the tested onco-
genic types, HPV-18, HPV-31, HPV-45, and HPV-58 (  Table 1  ). 
However, neutralizing antibody titers against HPV-16 were higher 
than against other types, although there was no clear relationship 
between titers and evolutionary distance of the heterologous types 
from HPV-16 (HPV-31 and HPV-58 are more closely related to 
HPV-16 than are HPV-18 and HPV-45, which are closely related 
to each other). 
  Because none of the alternative HPV-16 L2 peptides substan-
tially increased neutralizing titers to heterologous viruses, we 
examined concatenated fusion proteins, consisting of several 
homologous L2 peptides derived from different clinically rele-
vant HPV genotypes. Based on the above results and previous 
studies, L2 polypeptides corresponding to HPV-16 L2 17  –  36, 
11  –  88, and 11  –  200 were chosen for fusion constructs. We tested 
three multitype constructs: one with three copies of amino acids 
11  –  200 (termed 11-200 × 3 and derived from the L2 proteins of 
HPV-6, HPV-16, and HPV-18), one with ﬁ  ve copies of 11  –  88 
(termed 11-88 ×  5 and derived from L2 of HPV-1, HPV-5, 
HPV-6, HPV-16, and HPV-18), and one with 22 copies of 17  –  36 
(termed 17-36 × 22; see   Table 2   for the various HPV types used 
in this construct), with each L2 peptide being derived from clini-
cally relevant and diverse HPV genotypes (  Table 2  ) (  39  ). The 
proteins were expressed in   E coli  , afﬁ  nity puriﬁ  ed under denatur-
ing conditions, and used to vaccinate rabbits as described for the 
HPV-16 L2 polypeptides. In general, vaccination of each rabbit 
with the multitype L2 fusion proteins (11-200 × 3, 11-88 × 5, and 
17-36 × 22) in Freund’s adjuvant induced robust neutralization 
titers against the various HPVs in a given immunogen (  Table 1  ), 
although the 17-36 × 22, which included a peptide from each HPV 
type tested for neutralization, had relatively low titers against 
HPV-6 and HPV-31. Notably, vaccination with 11-200 ×  3 
  Table 1    .       Antibody responses of rabbits vaccinated with monomeric HPV-16 or multimeric HPV L2 polypeptides of different sizes  *     


















IVN   
    HPV-16 L2 
  polypeptides 
         1  –  88 a 409    600 204     800 409    600 200 3200 3200 12     800 1600 800 
         13  –  88    †   a 51    200 6400 3200 None None None 200   — 200 
         1  –  107 a 204  800 102  400 409  600 6400 12  800 6400 102  400 400 25  600 
  b 409  600 102  400 102  400 800 3200 400 6400  — 12    800 
         13  –  107 a 409  600 102  400 204  800 1600 3200 200 6400  — 6400 
         11  –  200 a 102  400 102  400 409  600 200 400 400 800 800 800 
         13  –  200 a 819  200 102  400 102  400 800 1600 3200 6400  — 12    800 
         89  –  200    †   a None None None None None None None None None 
  b 204  800 12 800 3200 None None None None  — None 
  Multimeric L2 
  constructs 
         17–36 x 22 a 409  600 102  400 204  800 12  800 800 12  800 25  600 800 3200 
  b 409  600 102  400 12  800 6400 None 3200 3200  — 400 
         11–88 x 5 a 819  200 819   200 819  200 204  800 51  200 102  400 409  600 102 400 >102  400 
  b 1638  400 819  200 819  200 102  400 102  400 102  400 409  600  — >102    400 
         11–200 x 3 a 409  600 102  400 204  800 25  600 1600 12  800 25  600 6400 1600 
  b 409  600 102  400 51  200 6400 1600 3200 12  800  — 800   
    *     Individual rabbits were vaccinated five times with 300   µ  g of the HPV-16 L2 polypeptides or polymeric L2 constructs using Freund’s adjuvant. Hyperimmune sera 
were collected at 1 week after the final vaccination and tested for L2-specific antibody by ELISA with microtiter plates coated with full-length HPV-16 L2 (HPV-16 
L2 ELISA) or HPV-16 L1/L2 pseudovirions (HPV-16 ELISA). The sera were also tested for IVN titers for the HPV pseudovirion types indicated. Neutralization titers 
were not detected in the preimmune sera. HPV    =    human papillomavirus; None    =    less than 50% neutralization at the lowest dilution tested of 1:50;   —      =    not tested; 
ELISA    =    enzyme-linked immunosorbent assay; IVN    =    in vitro neutralization.   
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induced strong cross-neutralizing titers against HPV-45, HPV-31, 
and HPV-58, although their peptides were not present in the 
immunogen (  Table 1  ). The immunogenicity of 11-88 × 5 was 
particularly impressive because it induced remarkably high titers 
of neutralizing antibodies to all the tested HPV types, including 
the three (HPV-31, HPV-45, and HPV-58) that were not repre-
sented in this fusion protein (  Table 1  ).         
    Responses in Rabbits Vaccinated With Gardasil 
  Vaccination with L1 VLPs can induce antibodies that cross-
neutralize very closely related papillomavirus types, for example, 
HPV-18 and HPV-45 (  16  ) (  22  ,  38  ). Therefore, we sought to com-
pare the levels of cross-neutralizing antibodies generated by vacci-
nation with Gardasil (which targets HPV-6, HPV-11, HPV-16, and 
HPV-18, and is formulated in aluminium salt), using two different 
concentrations, vs multitype L2 proteins formulated in CFA/IFA 
(  Table 3  ). As expected, vaccination with Gardasil produced high 
titers of neutralizing antibodies to the oncogenic HPV types 
included in the vaccine, HPV-16 and HPV-18. Even higher 
HPV-16 and HPV-18 titers were generated with the L2 fusion 
protein, but it should be noted that the rabbits received a higher 
dose of antigen for L2 than Gardasil, and the CFA/IFA adjuvant 
used for the L2 immunogen is more potent than aluminium salt. 
The most noteworthy differences between the rabbits vaccinated 
with Gardasil and those vaccinated with the L2 fusion protein were 
seen in the neutralizing titers against the heterologous HPV types. 
The sera from those receiving Gardasil consistently contained low, 
but detectable, levels of neutralizing activity against HPV-45 and 
occasionally against HPV-31 but had no detectable activity against 
HPV-58. However, the titers against the heterologous HPV types 
were 2  –  3 orders of magnitude lower than those against HPV-16 or 
HPV-18. By contrast, the sera from rabbits that were vaccinated 
with the L2 fusion protein had titers against the heterologous HPVs 
that were less than 1 order of magnitude lower than against the 
homologous HPVs.           
    Responses of Mice Vaccinated With Monomeric and 
Multimeric L2 Polypeptides 
  We also evaluated the immune response induced by the L2 immu-
nogens in mice, in part, to determine their neutralizing titers in a 
second animal species and in part as a prelude to vaccine protec-
tion studies because mice can be challenged with HPV pseudovi-
rions and infection quantified by delivery of a reporter such as 
luciferase (  34  ,  40  ). Mice were vaccinated three times at 2-week 
intervals with monovalent HPV-16 L2 polypeptides containing 
residues 17  –  36, 1  –  88, or 11  –  200, or one of the three concatenated 
multitype L2 fusion proteins, 11-200 × 3, 11-88 × 5, or 17-36 × 22, 
using the saponin-based GPI-0100 adjuvant (  41  ). Blood was col-
lected 2 weeks later, and the in vitro neutralization titers were 
determined for HPV-16, HPV-18, HPV-45, HPV-58 (four com-
mon oncogenic HPV types), and HPV-6 (the most common type 
found in benign genital warts). As had been observed in the rab-
bits, vaccination of mice with HPV-16 L2 1  –  88 or HPV-16 L2 
11  –  200 in GPI-0100 induced robust titers of neutralizing antibod-
ies against the homologous virus type, HPV-16, although the 
titers were approximately 2 orders of magnitude lower than in the 
rabbits vaccinated using Freund’s adjuvant (  Figure 1  ). However, 
vaccination with a synthetic peptide comprising HPV-16 L2 resi-
dues 17  –  36 (which had not been tested in the rabbits) did not 
induce detectable neutralizing antibodies, or L2-specific antibod-
ies (not shown), probably because it lacks a T-helper epitope for 
this mouse strain (  25  ). The positive control, vaccination of mice 
with HPV-16 L1 VLPs in the absence of adjuvant, induced even 
higher titers of HPV-16  –  neutralizing antibodies than the HPV-16 
L2 constructs (  P   < .001). In contrast, vaccination with HPV-45 L1 
VLPs failed to induce HPV-16  –  neutralizing antibodies, consistent 
with the type-restricted response to L1 VLP vaccines (  Figure 1  ). 
Vaccination with L2 11-88 × 5, 1-88 × 1, 11-200 × 3, and 11-200 × 1 
constructs generated statistically similar HPV-16  –  neutralizing 
  Table 2    .       A summary of the multitype HPV L2 constructs  *     




Types of HPV (in order 
from amino to carboxyl 
terminus)   
    1  –  88 × 1 16 16 
  11  –  200 × 1 26 16 
  11  –  200 × 3 63 6, 16, 18 
  11  –  88 × 5 43 16, 18, 1, 5, 6 
  17  –  36 × 22 49 1, 2, 63, 5, 8 (cutaneous) 
  6, 11 (mucosal low risk) 
  16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73, 82 
(mucosal high risk)   
    *     HPV    =    human papillomavirus.     
  Table 3    .       Antibody responses of rabbits vaccinated with Gardasil  *     
    Antigen,   µ  g Rabbit HPV-16 IVN HPV-18 IVN HPV-31 IVN HPV-45 IVN HPV-58 IVN   
    Gardasil, 30 a 51 200 51 200 50 100 None 
  b 25 600 51 200 None 100 None 
  c 25 600 25 600 None 800 None 
  d 51 200 102 400 50 800 None 
  Gardasil, 12 a 12 800 25 600 None None None 
  b 51 200 25 600 200 1600 None 
  c 51 200 25 600 None 800 None 
  d 102 400 51 200 50 400 None   
    *     Rabbits were vaccinated four times with either 30 or 12   µ  g of Gardasil. Hyperimmune sera were collected at 1 week after the final immunization and tested for 
IVN titers for the HPV pseudovirion types indicated in comparison with a control serum of a rabbit that was vaccinated five times with 300   µ  g of the polymeric 
L2 constructs 11-88 × 5 using Freund’s adjuvant, and shown in   Table 1  , rabbit a. Neutralization titers were not detected in the preimmune sera. None    =    less than 
50% neutralization at the lowest dilution tested of 1:50; HPV    =    human papillomavirus; IVN    =    in vitro neutralization.     jnci.oxfordjournals.org    JNCI | Articles 787
antibody titers in this small study. The 17-36 × 22 construct was 
less effective than 11-88 × 5 (  P   < .001;   Figure 1  ), possibly as a 
result of weak CD4 T-cell help (  25  ). The cross-neutralizing anti-
body responses observed in mice vaccinated with monotype 
HPV-16 L2 polypeptides in GPI-0100 were less robust than those 
generated in rabbits receiving the same vaccines in CFA/IFA. 
However, vaccination with 11-200 × 3 or 11-88 × 5 was very effec-
tive in inducing cross-neutralizing antibodies against HPV-45 and 
HPV-58, even though the fusion proteins do not contain sequences 
from either of these HPV types, in addition to inducing neutral-
izing antibodies against HPV-6 and HPV-18, which are repre-
sented in the fusion proteins (  Figure 1  ).           
    Responses of Mice Vaccinated With L2 Multimeric 
Polypeptides in Adjuvant 
  Several adjuvants that are potentially more effective than, or can be 
complementary to, alum have shown promise in clinical vaccine 
trials, for example, the immunostimulatory sequence (ISS) 1018, 
an oligonucleotide that activates toll-like receptor 9 (  42  ,  43  ), and 
the saponin-based adjuvant GPI-0100 (  44  ,  45  ). To address whether 
a particular adjuvant was more effective at inducing HPV-
neutralizing antibodies when formulated with a multitype L2 vac-
cine, we compared immune responses to 25   µ  g 11-200 ×  3 
formulated in a variety of adjuvants, and combinations thereof. 
However, when sera were obtained from mice 2 weeks after their 
third immunization and in vitro neutralization of HPV-16, 
HPV-18, HPV-45, and HPV-58 (  Figure 2  ) were measured, the 
titers were remarkably similar across each adjuvant group, and 
none was notably superior to alum-adjuvanted 11-200 × 3 at this 
time point.         
  Adjuvants can increase peak titers and the longevity of antibody 
responses. To assess the possibility that differences between adju-
vants might become clearer as humoral responses wane, the mice 
were challenged with HPV-16 pseudovirions at 4 months after vac-
cination. Cutaneous infection was detected as a bioluminescent signal 
3 days after the administration of HPV-16 pseudovirions carrying a 
luciferase reporter, immediately after injection of the challenged mice 
with the reporter substrate, luciferin. HPV-16 infection was statisti-
cally signiﬁ  cantly reduced after vaccination with 11-200 × 3 alone 
compared with after PBS control vaccination (  P   = .004;   Figure 3  ); 
reduction with 11-200 × 3 in any of the adjuvants tested compared 
with PBS control vaccination was even greater (  P   < .001;   Figure 3  ). 
In particular, the formulation of 11-200 × 3 with alum + 1018 ISS was 
more effective than 11-200 × 3 alone (  P   < .001) or with alum adjuvant 
(  P   = .001). GPI-0100 formulations tested with 11-200 × 3 were more 
effective than 11-200 × 3 alone (  P   < .001) or 11-200 × 3 in combina-
tion with alum (  P   < .001). We recently found that vaccination with 
GPI-0100 adjuvant alone had no statistically signiﬁ  cant effect on 
infectivity after HPV-16 challenge (  46  ). No statistically signiﬁ  cant 
difference in protection was observed when using only alum or only 
1018 ISS with 11-200 × 3 as compared with the protein alone.         
   
    Figure 1    .       A comparison of neutralizing antibody responses of mice vac-
cinated with multitype or monomeric L2 vaccines or with L1 VLP. 
BALB/c mice were vaccinated subcutaneously on days 0, 15, and 30 
with PBS or with 25   µ  g of different L2 monomeric and multitype con-
structs in GPI-0100 (50   µ  g) adjuvant or either HPV-16 L1 VLP or HPV-45 
L1 VLP without an adjuvant (ﬁ  ve mice per group). In vitro neutralization 
assays were performed using HPV pseudovirus for the genotypes indi-
cated on twofold dilutions of the antisera collected from the mice 
2 weeks after the ﬁ  nal vaccination. Endpoint titers achieving 50% neu-
tralization are plotted and the means shown as   horizontal lines  . 
HPV    =    human papillomavirus; PBS    =    phosphate-buffered saline; 
VLP    =    virus-like particle.         788   Articles | JNCI  Vol. 101, Issue 11  |  June 2, 2009
  Vaccination with HPV-16 L1 VLP alone, but not with 
HPV-45 L1 VLP, also gave a similar level of protection against 
HPV-16 challenge as vaccination with 11-200 × 3 with alum + 
1018 ISS or with GPI-0100 (  P   < .001; not shown). Therefore, we 
sought to compare the in vitro neutralizing antibody titers induced 
by vaccination of mice with Gardasil with those induced by vacci-
nation of mice with either 11-200 × 3 or 11-8 × 5 in the adjuvant 
  GPI-0100. The titers generated against HPV-16 and HPV-18, for 
which L1 VLPs are included in Gardasil, were substantially higher 
in the sera of mice that were vaccinated with Gardasil than in the 
sera of mice that were vaccinated with either multitype L2 con-
struct. However, no HPV-45  –   or HPV-58  –  neutralizing antibodies 
were detected in the sera of mice vaccinated with Gardasil, 
although some neutralizing activity against HPV-45 had been seen 
in the rabbits immunized with Gardasil (  Figure 4  ). In contrast, 
neutralizing antibody titers against HPV-45 and HPV-58 were 
readily detected in the sera of mice vaccinated with either 11-200 × 3 
or 11-88 × 5, although neither construct contains L2 sequences 
derived from these two HPV types.             
    Discussion 
  We found that vaccination with the multimeric fusion proteins 
comprising the amino terminus of L2 of several HPV types 
induced robust neutralizing antibody titers, and when used with 
potent adjuvants, it also provided immunity from viral challenge 
even 4 months after immunization      . Immunization with these mul-
titype L2 fusion proteins also induced robust titers against all clini-
cally relevant HPV types tested, as compared with the weaker 
cross-neutralizing responses to L2 of a single HPV type or the 
type-restricted responses to L1 VLP. 
  Several previous studies (  18  ,  19  ,  24  ) showed that the amino ter-
minus of L2 is protective in multiple animal models. Vaccination 
with L2 residues 94  –  122 provides relatively type-speciﬁ  c protec-
tion in rabbits (  23  ,  47  ), and studies in cattle (  48  ) suggest the value 
of L2 101  –  120, 131  –  151, and 151  –  170 for protection against 
BPV-4. Other studies (  48    –    51  ) support residues 108  –  120 as a cross-
neutralization epitope. We recently deﬁ  ned L2 residues 17  –  36 as 
an important protective epitope (  25  ,  34  ), and others have deﬁ  ned 
neutralization epitopes between residues 36  –  49 (  52  ) and 69  –  81 
(  48  ). Here, little difference was noted in the HPV-16 and heter-
ologous type  –  neutralizing antibody titers produced by vaccination 
with HPV-16 L2 13  –  200 and 1  –  88. These ﬁ  ndings are consistent 
with earlier reports that the ﬁ   rst 88 residues of L2 contain 
important neutralization epitopes (  26  ) and suggest that the amino-
terminal 13 residues are dispensable for a robust neutralizing 
antibody response, probably because they would be eliminated by 
furin cleavage during infection (  37  ,  38  ). However, removal of this 
peptide did not increase the ability of amino-terminal L2 peptides 
to induce neutralizing antibodies.     
    Figure 2    .       Neutralizing antibody responses of mice vaccinated with mul-
titype L2 protein alone or in various adjuvant combinations. BALB/c 
mice (ﬁ  ve mice per group) were vaccinated on days 0, 15, and 30 sub-
cutaneously with alum alone (1.3 mg), or 1018 ISS alone (10   µ  g/mouse), 
or PBS, or 25   µ  g 11-200 × 3 alone, or formulated with alum (1.3 mg), 
or with 1018 ISS (10   µ  g/mouse), or with GPI-0100 (at either 50 or 
200   µ  g/mouse), or with GPI-0100 (50   µ  g/mouse) + Tween-40 (1 mg/
mouse), or with alum and 1018 ISS (10   µ  g/mouse). In vitro neutralization 
titers were performed with two dilutions of the antisera of mice col-
lected 2 weeks after ﬁ  nal immunization using HPV pseudovirus for the 
genotypes indicated. Endpoint titers for 50% neutralization are plotted 
and the means shown as   horizontal lines  . HPV    =    human papillomavirus; 
PBS    =    phosphate-buffered saline.         jnci.oxfordjournals.org    JNCI | Articles 789
  Taking advantage of the presence of L2 epitopes that can 
induce broadly cross-reactive neutralizing antibodies could confer 
protection against a wide spectrum of HPV types. In support of 
this possibility, immunization with heterologous L2 polypeptides 
protects rabbits against CRPV, a model that was used in L1 VLP 
vaccine development (  24  ,  25  ). The production in bacteria of a 
single polypeptide, as with an L2 fusion protein, should be sub-
stantially less expensive to manufacture than a polyvalent L1 VLP 
vaccine. If an L2 vaccine were proven effective in people, its sim-
pler manufacturing process could make the local production of 
such a vaccine highly feasible, which might achieve the goal of 
producing it at sustainable prices in emerging countries and lead to 
its widespread implementation in the developing world. 
  L1 VLPs induce high titer and long-lasting protective antibody 
responses even without adjuvant (  53  ). A potentially serious limita-
tion of the L2 approach has been that the level of cross-neutralizing 
antibodies against heterologous HPV types has been lower than that 
against the homologous virus, which has been associated with 
heterologous L2 vaccination inducing less effective protection than 
homologous L2 vaccination (  24  ). To produce a practical vaccine, it 
is necessary for protection to last at least several years, and the less 
robust activity against heterologous HPV types raises doubts about 
whether sufﬁ  cient protection of long duration would be induced by 
a monotype L2 immunogen and suggests the need for a potent 
adjuvant (  54  ). Here, we examined multiple adjuvants (alum, 
  GPI-0100, and 1018 ISS) that have been used in substantial num-
bers of patients and act via diverse mechanisms (  44  ,  55  ,  56  ). GPI-0100 
and 1018 ISS did not confer an obvious improvement in the peak 
humoral response to 11-200 × 3 as compared with alum, but there 
were statistically signiﬁ  cant differences in protection from HPV-16 
pseudovirus challenge at 4 months after immunization. Alum + 1018 
ISS or GPI-0100 was more effective when used with 11-200 × 3 than 
alum alone or 1018 ISS alone and achieved long-term protection in 
this model on par with that of L1 VLP. McGarvie et al. (  57  ) found 
that cattle were strongly protected from BPV-4 challenge 1 year 
after vaccination with 1 mg BPV-4 L2 in IFA twice      , suggesting the 
potential for long-term immunity with other adjuvants. 
  The ability of an L2 fusion protein to increase the immune 
response to HPV types not present in the immunogen, although 
not as robust as its reactivity against those HPV types whose L2 
peptides are represented in the fusion protein, strongly suggests 
that multitype fusion proteins may have the capacity to protect 
against a broad range of HPV types and that such protection could 
be of long duration. This more potent and broadly effective immune 
response may reﬂ  ect enhanced cross-linking and activation of those 
B cells that recognize L2-speciﬁ  c neutralizing epitopes common to 
multiple HPV types in the fusion constructs and a resulting bias 
toward production of cross-neutralizing antibodies (  30  ,  31  ). 
  We made direct comparisons in two animal models between 
Gardasil, an L1 VLP vaccine that has been licensed in the United 
States, and the L2 fusion proteins. Although the responses were 
generally comparable, L2-speciﬁ  c cross-neutralization was weaker 
in mice than in rabbits. These analyses veriﬁ  ed ﬁ  rst that the L2 
vaccines can induce strong neutralizing activity and protection 
against homologous HPV types, although the L2 immunogens are 
somewhat less potent immunologically than L1 VLPs against 
HPV types represented in the respective vaccine. However, the 
striking difference between L1 VLPs and the L2 fusion proteins 
was the limited cross-neutralizing activity induced by the VLP 
vaccine, in comparison with the robust activity displayed by the 
L2-based immunogens. Vaccination with Gardasil protects patients 
against HPV-6, HPV-11, HPV-16, and HPV-18, and efforts to 
assess cross-protection against types not used to make this vaccine 
are ongoing (  58  ). Although there have been no clinical studies of 
an L2 vaccine in a prophylactic setting to date, vaccination of 
patients with HPV-16 L2 can trigger cross-neutralizing antibody 
responses even without an adjuvant (  54  ). 
  11-200 × 3 is composed of L2 peptides from HPVs that cause 
genital infection (HPV-6, HPV-16, and HPV-18), and 11-88 × 5 
contains peptides from these three HPV types plus those from 
HPV-1, which is from a phylogenetic group that causes nongenital 
warts, and HPV-5, from another phylogenetic group that also 
   
    Figure 3    .       In vivo HPV-16 pseudovirus challenge of mice 4 months after 
vaccination with L2 11-200 × 3 in different adjuvant combinations. Mice 
(ﬁ  ve per group, the same mice as in   Figure 2  ) were vaccinated three 
times at 2-week intervals with PBS, 10   µ  g of L1 VLPs, or 25   µ  g of L2 
11-200 × 3 in different adjuvants or adjuvant alone. Individual groups 
are as listed below from left to right: PBS alone, 11-200 × 3 alone, alum 
alone (1.3 mg), 11-200 × 3 + alum (1.3 mg), 1018 ISS alone (10   µ  g/
mouse), 11-200 × 3    +    1018 ISS (10   µ  g/mouse), 11-200 × 3 + alum + 1018 
(10   µ  g/mouse), 11-200 × 3 + GPI-0100 (50   µ  g/mouse), 11-200 × 3 + GPI-
0100 (200   µ  g/mouse), 11-200 × 3 + GPI-0100 (50   µ  g/mouse) + Tween-40 
(1 mg/mouse). Approximately 4 months after the vaccination, a patch 
on the belly of each anesthetized BALB/c mouse was shaved with an 
electric razor without traumatizing the epithelium. Mice were then chal-
lenged with 3 × 10 
9   HPV-16 pseudovirions (100 ng) in 10   µ  L of 0.6% 
carboxymethylcellulose carrying a luciferase reporter construct. Three 
days later, the mice were anesthetized and injected with luciferin. 
Images were acquired for 10 minutes with a Xenogen IVIS 200 biolumi-
nescence imaging system. Equal-sized areas encompassing the site of 
inoculation were analyzed using Living Image 2.20 software, and the 
luminescence units were plotted using levels in mice vaccinated with 
HPV-16 L1 VLP before challenge as baseline. Individual data points and 
means (  horizontal lines  ) are shown. HPV    =    human papillomavirus; 
ISS    =    immunostimulatory sequence; PBS    =    phosphate-buffered saline; 
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infects nongenital cutaneous sites. Infection by viruses related to 
HPV-5 may be asymptomatic, induce benign lesions, or be present 
in a subset of cutaneous squamous cell cancers. A potential advan-
tage of 11-88 × 5 is that it might confer more potent protection 
against HPVs that infect nongenital cutaneous sites than 11-200 × 3, 
although both might be expected to confer a similar degree of 
  protection against cutaneous and mucosal genital HPV infection. 
In mice, 11-88 × 5 and 11-200 × 3 showed similar potency against 
the HPVs that cause genital infection, but in rabbits, 11-88 × 5 
induced stronger immunity to them than 11-200 × 3. In contrast to 
genital HPV infection, nongenital HPV infection is not usually 
sexually transmitted and frequently occurs in children. If future 
clinical testing of an immunogen similar to 11-88 × 5 were to show 
protection against infection at nongenital cutaneous sites in addi-
tion to protection against genital infection, it could provide a medi-
cal rationale for giving an L2-based vaccine in a time frame similar 
to that of childhood vaccines. Administration of an HPV vaccine to 
young children could render moot the theoretical issue that HPV 
vaccination of adolescents might inﬂ  uence their sexual behavior. 
  Oncogenic HPV infection causes approximately 5% of all can-
cer deaths globally. Its impact is greatest for women who are 
currently not reached by effective cervical cancer screening pro-
grams because approximately 80% of cervical cancers occur in 
low-resource settings in the developing world, and this malignancy 
accounts for the vast majority of cancer-related deaths attributable 
to HPV infection (  59  ,  60  ). If widely implemented, the current 
L1 VLP HPV vaccines have the potential to produce a dramatic 
drop in cervical cancer rates. However, these vaccines are currently 
too expensive for population-wide implementation in those set-
tings that might beneﬁ  t most from such a vaccine. Furthermore, 
because nearly a third of cervical cancer is caused by oncogenic 
HPV types not included in current HPV vaccine formulations, the 
type-restricted protection induced by the L1 VLP vaccines means 
that cervical cancer screening must remain in place in the industri-
alized world. In these settings, therefore, the cost of HPV vaccina-
tion must be borne in addition to that of screening, although cost 
savings might be achieved by altering the interval and/or modality 
by which vaccinated women are screened. Thus, it would be highly 
desirable to develop a more affordable vaccine for the developing 
world as well as to broaden protection against oncogenic HPV 
infections to a degree that would permit a major reduction in 
screening in the industrialized world. Although increasing the 
valency of the current L1 VLP vaccines represents a logical 
approach to overcome the latter problem (  51  ), it seems likely that 
such a second-generation vaccine would, for many years, continue 
to be too expensive for widespread use in low-resource settings. 
  The weaker immune responses to multitype L2 vaccines as 
compared with L1 VLP raise concerns about the longevity of the 
response and the potential need to use adjuvant stronger than alum 
to achieve and maintain for the long-term comparable levels of 
immunity. Correlates of protection have not yet been deﬁ  ned for 
immunity in patients who have received HPV vaccines, although 
the presence of neutralizing antibody is likely important. Clinical 
studies are warranted to assess the safety and immunogenicity of 
multitype L2 vaccines in alum and other adjuvant formulations.         
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